Skip to content
2000
Volume 12, Issue 4
  • ISSN: 1573-4064
  • E-ISSN: 1875-6638

Abstract

Background: Fibroblast growth factor (FGF) receptors (FGFRs) play a key role in tumor growth and angiogenesis. The present report describes our search for an extracellularly binding FGFR inhibitor using a combined molecular modeling and de novo design strategy. Methods: Based upon crystal structures of the receptor with its native ligand and knowledge of inhibiting peptides, we have developed a computational protocol that predicts the putative binding of a molecule to the extracellular domains of the receptor. This protocol, or scoring function, was used in combination with the de novo synthesis program 'SYNOPSIS' to generate high scoring and synthetically accessible compounds. Results: Eight compounds belonging to 3 separate chemical classes were synthesized. One of these compounds, alofanib (RPT835), was found to be an effective inhibitor of the FGF/FGFR2 pathway. The preclinical in vitro data support an allosteric inhibition mechanism of RPT835. RPT835 potently inhibited growth of KATO III gastric cancer cells expressing FGFR2, with GI50 value of 10 nmol/L. Conclusion: These results provide strong rationale for the evaluation of compound in advanced cancers.

Loading

Article metrics loading...

/content/journals/mc/10.2174/1573406412666160106154726
2016-06-01
2025-06-13
Loading full text...

Full text loading...

/content/journals/mc/10.2174/1573406412666160106154726
Loading

  • Article Type:
    Research Article
Keyword(s): allosteric inhibitor; alofanib; Fibroblast growth factor receptor 2; RPT835
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test